Memory Enhancer Succeeds in Phase II Alzheimer's Trial

(MedPage Today) -- SEATTLE--A first-in-class oral compound targeting N-methyl-D-aspartate (NMDA) receptors proved beneficial in a mid-stage clinical trial in Alzheimer's disease, setting the groundwork for a full safety and efficacy study...